Summary.
Addition of the catechol-O-methyltransferase (COMT) inhibitor entacapone (EN) prolongs plasma metabolism of levodopa (LD). Objectives were to determine the clinical response after EN addition and the plasma degradation of LD and 3-O-methyldopa [3-OMD]. Not optimum treated hospitalised patients with Parkinson’s disease received the same LD dosage on the first day only with carbidopa (CD) and on the second day with CD and EN (t.i.d.) within a standardised setting. We scored motor symptoms and measured LD- and 3-OMD levels on both days at fixed moments. Motor impairment significant better improved probably due to significant higher maximum concentrations [Cmax] and computed area under the curve values of LD levels during the LD/CD/EN condition. Time to Cmax of LD was significantly delayed after the first two LD/CD/EN intakes. An impact of EN on 3-OMD levels appeared. A possibly augmented LD absorption and a prolonged LD metabolism after EN supplementation may contribute to a more continuous LD delivery to the brain.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
P Benetello M Furlanut M Fortunato F Pea M Baraldo (1997) ArticleTitleLevodopa and 3-O-methyldopa in cerebrospinal fluid after levodopa-carbidopa association Pharmacol Res 35 313–315 Occurrence Handle9264047 Occurrence Handle1:CAS:528:DyaK2sXls1yhsbY%3D Occurrence Handle10.1006/phrs.1997.0145
MA Evans GA Broe EJ Triggs M Cheung H Creasey PD Paull (1981) ArticleTitleGastric emptying rate and the systemic availability of levodopa in the elderly parkinsonian patient Neurology 31 1288–1294 Occurrence Handle7202139 Occurrence Handle1:STN:280:Bi2B2s3ptl0%3D
S Fahn D Oakes I Shoulson K Kieburtz A Rudolph A Lang CW Olanow C Tanner K Marek (2004) ArticleTitleLevodopa and the progression of Parkinson’s disease N Engl J Med 351 2498–2508 Occurrence Handle15590952 Occurrence Handle1:CAS:528:DC%2BD2cXhtVGksbnE Occurrence Handle10.1056/NEJMoa033447
CG Goetz PA LeWitt M Weidenman (2003) ArticleTitleStandardized training tools for the UPDRS activities of daily living scale: newly available teaching program Mov Disord 18 1455–1458 Occurrence Handle14673881 Occurrence Handle10.1002/mds.10591
AJ Hughes SE Daniel L Kilford AJ Lees (1992) ArticleTitleAccuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases J Neurol Neurosurg Psychiatry 55 181–184 Occurrence Handle1564476 Occurrence Handle1:STN:280:By2B38nnsFQ%3D Occurrence Handle10.1136/jnnp.55.3.181
S Kaakkola H Teravainen S Ahtila H Rita A Gordin (1994) ArticleTitleEffect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients Neurology 44 77–80 Occurrence Handle8290096 Occurrence Handle1:STN:280:ByuC3MbktFU%3D
W Koller M Guarnieri J Hubble AL Rabinowicz D Silver (2004) ArticleTitleAn open-label evaluation of the tolerability and safety of Stalevo (R) (carbidopa, levodopa and entacapone) in Parkinson’s disease patients experiencing wearing-off J Neural Transm 112 221–230 Occurrence Handle15503197 Occurrence Handle10.1007/s00702-004-0184-1 Occurrence Handle1:CAS:528:DC%2BD2MXkvFGhtQ%3D%3D
R Kurlan KP Rothfield WR Woodward JG Nutt C Miller D Lichter I Shoulson (1988) ArticleTitleErratic gastric emptying of levodopa may cause “random” fluctuations of parkinsonian mobility Neurology 38 419–421 Occurrence Handle3126408 Occurrence Handle1:STN:280:BieC2MjhtlI%3D
PT Männisto S Kaakkola E Nissinen IB Linden P Pohto (1988) ArticleTitleProperties of novel effective and highly selective inhibitors of catechol-O-methyltransferase Life Sci 43 1465–1471 Occurrence Handle3185103 Occurrence Handle10.1016/0024-3205(88)90258-5
S Muhlack D Woitalla J Welnic S Twiehaus H Przuntek T Müller (2004) ArticleTitleChronic levodopa intake increases levodopa plasma bioavailability in patients with Parkinson’s disease Neurosci Lett 363 284–287 Occurrence Handle15182961 Occurrence Handle1:CAS:528:DC%2BD2cXks1CjtL4%3D Occurrence Handle10.1016/j.neulet.2004.04.012
T Müller B Voss K Hellwig SF Josef T Schulte H Przuntek (2004) ArticleTitleTreatment benefit and daily drug costs associated with treating Parkinson’s disease in a Parkinson’s disease clinic CNS Drugs 18 105–111 Occurrence Handle14728057 Occurrence Handle10.2165/00023210-200418020-00004
T Müller D Woitalla D Schulz S Peters W Kuhn H Przuntek (2000) ArticleTitleTolcapone increases maximum concentration of levodopa J Neural Transm 107 113–119 Occurrence Handle10809409 Occurrence Handle10.1007/s007020050010
M Murata I Kanazawa (1997) ArticleTitleEffects of chronic levodopa therapy on dopa pharmacokinetics Eur Neurol 38 IssueID[Suppl 2] 50–55 Occurrence Handle9387803 Occurrence Handle1:CAS:528:DyaK2sXnslyltrs%3D
E Nissinen R Tuominen V Perhoniemi S Kaakkola (1988) ArticleTitleCatechol-O-methyltransferase activity in human and rat small intestine Life Sci 42 2609–2614 Occurrence Handle3386403 Occurrence Handle1:CAS:528:DyaL1cXkt1Sls7c%3D Occurrence Handle10.1016/0024-3205(88)90330-X
JG Nutt (1998) ArticleTitleCatechol-O-methyltransferase inhibitors for treatment of Parkinson’s disease Lancet 351 1221–1222 Occurrence Handle9643737 Occurrence Handle1:STN:280:DyaK1czgsFyqsg%3D%3D Occurrence Handle10.1016/S0140-6736(05)79311-9
JG Nutt (2000) ArticleTitleEffect of COMT inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients Neurology 55 S33–S37 Occurrence Handle11147508 Occurrence Handle1:CAS:528:DC%2BD3MXhtFOlsw%3D%3D
CW Olanow K Kieburtz M Stern R Watts JW Langston M Guarnieri J Hubble (2004) ArticleTitleDouble-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease Arch Neurol 61 1563–1568 Occurrence Handle15477510 Occurrence Handle1:STN:280:DC%2BD2crgslajsQ%3D%3D Occurrence Handle10.1001/archneur.61.10.1563
PS Papavasiliou GC Cotzias SE Duby AJ Steck C Fehling MA Bell (1972) ArticleTitleLevodopa in Parkinsonism: potentiation of central effects with a peripheral inhibitor N Engl J Med 286 8–14 Occurrence Handle4550085 Occurrence Handle1:STN:280:CS2D2MnlvV0%3D
W Poewe (2004) ArticleTitleThe role of COMT inhibition in the treatment of Parkinson’s disease Neurology 62 S31–S38 Occurrence Handle14718678 Occurrence Handle1:CAS:528:DC%2BD2cXhtVOjs7fI Occurrence Handle10.1159/000080906
E Schultz S Tarpila AC Backstrom A Gordin E Nissinen P Pohto (1991) ArticleTitleInhibition of human erythrocyte and gastroduodenal catechol-O-methyltransferase activity by nitecapone Eur J Clin Pharmacol 40 577–580 Occurrence Handle1884738 Occurrence Handle1:CAS:528:DyaK3MXlt1Kru7o%3D
LA Smith MJ Jackson MJ Hansard E Maratos P Jenner (2003) ArticleTitleEffect of pulsatile administration of levodopa on dyskinesia induction in drug-naive MPTP-treated common marmosets: effect of dose, frequency of administration, and brain exposure Mov Disord 18 487–495 Occurrence Handle12722161 Occurrence Handle10.1002/mds.10394
DG Waller C Roseveare AG Renwick B Macklin CF George (1991) ArticleTitleGastric emptying in healthy volunteers after multiple doses of levodopa Br J Clin Pharmacol 32 691–695 Occurrence Handle1768561 Occurrence Handle1:CAS:528:DyaK38XhsVehsLw%3D
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Müller, T., Erdmann, C., Muhlack, S. et al. Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa/carbidopa with and without entacapone in patients with Parkinson’s disease. J Neural Transm 113, 1441–1448 (2006). https://doi.org/10.1007/s00702-006-0442-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00702-006-0442-5